---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-048001"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2025-05-28T23:59:59+00:00"
generated_at: "2026-05-20T08:45:30.820952+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incannex cancels 172M Series A warrants, eliminating up to 347.2M shares from dilution

## Summary
- Agreement to cancel remaining 172M Series A warrants; cancellation payment up to $12.2M.
- Combined with earlier cancellation (175.2M), total elimination of up to 347.2M potential shares.
- Move ahead of Phase 2 RePOSA trial data for IHL-42X in sleep apnea expected July 2025.
- CEO Joel Latham cites strengthening capital structure and proactive dilution management.

## SEC filing metadata
- accession: 0001213900-25-048001
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2025-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390025048001/0001213900-25-048001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390025048001/ea0243460-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-048001
- JSON: https://secwatch.observer/filing/0001213900-25-048001.json
- Plain text: https://secwatch.observer/filing/0001213900-25-048001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.